PMID- 1993227
OWN - NLM
STAT- MEDLINE
DCOM- 19910320
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 77
IP  - 4
DP  - 1991 Feb 15
TI  - Detection of early human T-cell lymphotropic virus type I antibody patterns 
      during seroconversion among transfusion recipients.
PG  - 896-905
AB  - From a cohort of human T-cell lymphotropic virus type I (HTLV-I) exposed 
      transfusion recipients (N = 71) enrolled in the Jamaican Transfusion Study, 11 
      were selected for detailed laboratory evaluation. All recipients were followed at 
      monthly intervals for 6 months and then bimonthly up to 1 year for evidence of 
      HTLV-I seroconversion. Without regard to results on screening assays, 
      pretransfusion and posttransfusion samples were tested with two licensed HTLV-1 
      whole-virus screening enzyme immunoassays (EIAs), recombinant EIAs for antibody 
      against tax (p40x) and p21e envelope, standard whole virus Western blot (WB), WB 
      enhanced with recombinant p21e, and radioimmunoprecipitation assay (RIPA). In the 
      early period posttransfusion, antibody to gag core protein was predominant with 
      anti-p24 generally appearing before anti-p19. Recombinant anti-p21e envelope 
      protein, in EIA and WB format, was frequently the earliest envelope reactivity 
      detected, while anti-gp46 in WB and anti-gp61/68 in RIPA system appeared later. 
      Anti-tax antibodies appeared later in the time course of seroconversion. The 
      whole-virus EIAs were less sensitive than the confirmatory assays. The 
      combination of WB and RIPA or WB enhanced with recombinant p21e appeared equally 
      effective in confirming samples as positive by the Public Health Service two gene 
      group confirmatory algorithm. However, specificity of this assay approach could 
      not be addressed in this study.
FAU - Manns, A
AU  - Manns A
AD  - National Cancer Institute, Bethesda, MD 20892.
FAU - Murphy, E L
AU  - Murphy EL
FAU - Wilks, R
AU  - Wilks R
FAU - Haynes, G
AU  - Haynes G
FAU - Figueroa, J P
AU  - Figueroa JP
FAU - Hanchard, B
AU  - Hanchard B
FAU - Barnett, M
AU  - Barnett M
FAU - Drummond, J
AU  - Drummond J
FAU - Waters, D
AU  - Waters D
FAU - Cerney, M
AU  - Cerney M
AU  - et al.
LA  - eng
GR  - N01-CP-31006/CP/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Antigens, Viral)
RN  - 0 (Gene Products, env)
RN  - 0 (Gene Products, gag)
RN  - 0 (Gene Products, tax)
RN  - 0 (HTLV-I Antibodies)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Viral Envelope Proteins)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, Viral/immunology
MH  - *Blood Transfusion
MH  - Blotting, Western
MH  - Female
MH  - Gene Products, env/immunology
MH  - Gene Products, gag/immunology
MH  - Gene Products, tax/immunology
MH  - HTLV-I Antibodies/*blood
MH  - HTLV-I Infections/immunology/*transmission
MH  - Human T-lymphotropic virus 1/immunology
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Jamaica
MH  - Male
MH  - Recombinant Proteins/immunology
MH  - Viral Envelope Proteins/immunology
EDAT- 1991/02/15 00:00
MHDA- 1991/02/15 00:01
CRDT- 1991/02/15 00:00
PHST- 1991/02/15 00:00 [pubmed]
PHST- 1991/02/15 00:01 [medline]
PHST- 1991/02/15 00:00 [entrez]
AID - S0006-4971(20)85335-X [pii]
PST - ppublish
SO  - Blood. 1991 Feb 15;77(4):896-905.